Cumulative effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease in China

被引:11
|
作者
Chen, Jing-Feng [1 ]
Wu, Zhuo-Qing [2 ]
Liu, Hao-Shuang [1 ]
Yan, Su [1 ]
Wang, You-Xiang [3 ]
Xing, Miao [4 ]
Song, Xiao-Qin [1 ]
Ding, Su-Ying [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Hlth Management Ctr, 1 Longhu Middle Ring Rd, Zhengzhou 450052, Henan, Peoples R China
[2] Dalian Univ Technol, Inst Syst Engn, Dalian 116024, Liaoning, Peoples R China
[3] Zhengzhou Univ, Coll Publ Hlth, Zhengzhou 450001, Henan, Peoples R China
[4] Henan Univ Sci & Technol, Sch Basic Med & Forens Med, Luoyang 471003, Henan, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
Metabolic dysfunction-associated fatty liver disease; High-normal alanine aminotransferase level; Cumulative effect; Cox proportional hazards regression; Cohort study; LYMPH-NODE METASTASIS; ESOPHAGEAL; MORTALITY; NOMOGRAM;
D O I
10.3748/wjg.v30.i10.1346
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND Within the normal range, elevated alanine aminotransferase (ALT) levels are associated with an increased risk of metabolic dysfunction-associated fatty liver disease (MAFLD). AIM To investigate the associations between repeated high-normal ALT measurements and the risk of new-onset MAFLD prospectively. METHODS A cohort of 3553 participants followed for four consecutive health examinations over 4 years was selected. The incidence rate, cumulative times, and equally and unequally weighted cumulative effects of excess high-normal ALT levels (ehALT) were measured. Cox proportional hazards regression was used to analyse the association between the cumulative effects of ehALT and the risk of new-onset MAFLD. RESULTS A total of 83.13% of participants with MAFLD had normal ALT levels. The incidence rate of MAFLD showed a linear increasing trend in the cumulative ehALT group. Compared with those in the low-normal ALT group, the multivariate adjusted hazard ratios of the equally and unequally weighted cumulative effects of ehALT were 1.651 [95% confidence interval (CI): 1.199-2.273] and 1.535 (95%CI: 1.119-2.106) in the third quartile and 1.616 (95%CI: 1.162-2.246) and 1.580 (95%CI: 1.155-2.162) in the fourth quartile, respectively. CONCLUSION Most participants with MAFLD had normal ALT levels. Long-term high-normal ALT levels were associated with a cumulative increased risk of new-onset MAFLD.
引用
收藏
页码:1346 / 1357
页数:13
相关论文
共 50 条
  • [41] Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy
    Jianan Zhao
    Yiyang Hu
    Jinghua Peng
    Cellular & Molecular Biology Letters, 2021, 26
  • [42] Luteolin alleviates metabolic dysfunction-associated fatty liver disease induced by a high-fat diet in rats
    Taweesap, Pongsakorn
    Yuenyong, Ittipon
    Potue, Prapassorn
    Khamseekaew, Juthamas
    Iampanichakul, Metee
    Pakdeechote, Poungrat
    Maneesai, Putcharawipa
    ACTA PHYSIOLOGICA, 2024, 240 : 42 - 42
  • [43] Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement"
    Mak, Lung-Yi
    Yuen, Man-Fung
    Seto, Wai-Kay
    JOURNAL OF HEPATOLOGY, 2020, 73 (06) : 1573 - 1574
  • [44] Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy
    Zhao, Jianan
    Hu, Yiyang
    Peng, Jinghua
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2021, 26 (01)
  • [45] The effects of SGLT2 inhibitors in patients with metabolic dysfunction-associated fatty liver disease; a narrative review
    Popoviciu, Mihaela Simona
    Paduraru, Lorena
    Rahman, Md Mominur
    Supti, Fatema Akter
    Stoica, Roxana Adriana
    Reurean-Pintilei, Delia
    Bica, Cristina Ioana
    Cavalu, Simona
    JOURNAL OF MIND AND MEDICAL SCIENCES, 2024, 11 (01): : 62 - 77
  • [46] Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edioron "Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis"
    Wu, Xiangyu
    Ni, Wenjing
    Chen, Qianqian
    Shi, Junping
    Li, Jie
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
  • [47] Illness perception, coping and psychological distress among patients with metabolic dysfunction-associated fatty liver disease (MAFLD) in China
    Chen, Liyuan
    Huang, Zhongxuan
    Jiang, Chenqi
    Wu, Chuanghong
    He, Shihua
    Zeng, Fangfang
    Huang, Shaofen
    Zhang, Fan
    BMC PUBLIC HEALTH, 2025, 25 (01)
  • [48] Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase
    Lopez-Suarez, Alejandro
    Rodriguez Guerrero, Jose Maria
    Elvira-Gonzalez, Javier
    Beltran-Robles, Manuel
    Canas-Hormigo, Francisco
    Bascunana-Quirell, Antonio
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 23 (11) : 1011 - 1017
  • [49] High-Sensitivity C-Reactive Protein Levels in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Alcohol-Associated Liver Disease (MetALD), and Alcoholic Liver Disease (ALD) with Metabolic Dysfunction
    Baek, Seong-Uk
    Yoon, Jin-Ha
    BIOMOLECULES, 2024, 14 (11)
  • [50] Amino acids profile in relation to metabolic dysfunction-associated fatty liver disease (MAFLD) in children with severe obesity - preliminary results
    Bugajska, J.
    Sekala, M.
    Wojcik, M.
    Berska, J.
    Tomasik, P.
    Sztefko, K.
    CLINICA CHIMICA ACTA, 2024, 558